Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Downgrades Rite Aid to 'Sell'


Merrill Lynch downgraded Rite Aid (RAD) to sell from neutral.

Analyst Mark Husson says the recent rally in Rite Aid's share price severely limits upside even if sales and earnings do better than expected. He says at current forecasts, he sees only downside in the price as this recovery story is nearly played out, and it cannot afford yet to grow.

Trading at about 30.1 times the fiscal 2005 (Feb.) earnings per share estimate, and 8.2 times the enterprise-value-to-EBITDA, Husson says the stock is more expensive than rival drugstore CVS. He thinks CVS is a stable, investment grade business that can afford to, and indeed is, growing as well as just "recovering."


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus